Edwards Lifesciences Corp (NYSE:EW) – SunTrust Banks lifted their Q1 2018 EPS estimates for Edwards Lifesciences in a research report issued to clients and investors on Wednesday. SunTrust Banks analyst B. Nudell now anticipates that the medical research company will earn $1.11 per share for the quarter, up from their previous estimate of $1.10. SunTrust Banks has a “Buy” rating and a $150.00 price objective on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences’ Q2 2018 earnings at $1.15 EPS, Q3 2018 earnings at $1.04 EPS, Q4 2018 earnings at $1.22 EPS, FY2018 earnings at $4.52 EPS, FY2019 earnings at $5.26 EPS, FY2020 earnings at $5.87 EPS, FY2021 earnings at $6.49 EPS and FY2022 earnings at $7.06 EPS.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.03. The firm had revenue of $888.50 million for the quarter, compared to analyst estimates of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. Edwards Lifesciences’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period last year, the company posted $0.75 EPS.
Edwards Lifesciences (NYSE EW) opened at $123.78 on Friday. The firm has a market cap of $27,447.10, a PE ratio of 42.98, a P/E/G ratio of 1.92 and a beta of 0.63. Edwards Lifesciences has a 12 month low of $89.20 and a 12 month high of $138.48. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.15.
Edwards Lifesciences announced that its board has authorized a stock buyback plan on Thursday, December 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.
In related news, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $104.76, for a total value of $1,986,249.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert W.A. Sellers sold 12,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $131.03, for a total transaction of $1,574,980.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 175,940 shares of company stock worth $20,049,578. Corporate insiders own 2.13% of the company’s stock.
Institutional investors have recently bought and sold shares of the stock. Cerebellum GP LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $128,000. Resources Investment Advisors Inc. increased its holdings in Edwards Lifesciences by 66.0% in the 4th quarter. Resources Investment Advisors Inc. now owns 1,170 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 465 shares during the last quarter. Exane Derivatives increased its holdings in Edwards Lifesciences by 381.3% in the 4th quarter. Exane Derivatives now owns 1,213 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 961 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at approximately $140,000. Finally, Dupont Capital Management Corp acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at approximately $142,000. Hedge funds and other institutional investors own 81.52% of the company’s stock.
WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/09/brokers-offer-predictions-for-edwards-lifesciences-corps-q1-2018-earnings-ew.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.